Why NovoCure Stock Is Crashing Today
Shares of NovoCure (NASDAQ: NVCR) were crashing 29.6% lower as of 10:19 a.m. ET on Tuesday. The steep decline came after the company announced data for its Tumor Treating Fields (TTFields) therapy in treating non-small cell lung cancer (NSCLC) that it's presenting today at the American Society of Clinical Oncology (ASCO) annual meeting.
NovoCure reported that patients receiving TTFields combined with standard therapies achieved median overall survival (OS) of 13.2 months, compared to 9.9 months for patients treated only with standard therapies. The company said that there was a "profound OS benefit" with a subgroup of patients who received immune checkpoint inhibitors (ICIs). Patients in this subgroup who received TTFields plus ICIs had a median OS of 18.5 months, compared to a median OS of 10.8 months for patients treated only with ICIs.
With this seemingly positive news, why did the healthcare stock plunge? Some analysts noted that only a few patients (66) were treated with ICIs. However, ICIs such as 's Keytruda and Bristol-Myers Squibb's Opdivo are now the standard of care for NSCLC. There are concerns about whether NovoCure's data really reflects the likelihood of an impressive survival benefit for TTFields in the real world.
Source Fool.com
Merck KGaA Aktie
3 Buy-Einschätzungen und 4 Sell-Einschätzungen halten sich bei der Aktie die Waage.
Mit einem Kursziel von 135 € für Merck KGaA könnte eine leichte Minderung gegenüber dem aktuellen Kurs von 148.25 € erreicht werden.
